Progenics Pharmaceuticals Inc (PGNX)

8.64
NASDAQ : Health Care
Prev Close 8.67
Day Low/High 8.27 / 8.82
52 Wk Low/High 3.61 / 9.23
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 70.05M
Market Cap 607.35M
EPS -0.60
P/E Ratio 54.19
Div & Yield N.A. (N.A)

Latest News

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

Provides Non-Dilutive Funding to Advance Late-Stage Oncology Portfolio

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Oversold Conditions For Progenics Pharmaceuticals (PGNX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options

Commit To Buy Progenics Pharmaceuticals At $3, Earn 13.3% Using Options

Investors considering a purchase of Progenics Pharmaceuticals, Inc. stock, but tentative about paying the going market price of $5.67/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Biotech Bargain Bin Bursts With Bounty

Biotech Bargain Bin Bursts With Bounty

This sector is one of the few areas of the market where you'll find myriad compelling values.

3 Stocks for Growth in 2017

3 Stocks for Growth in 2017

BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

RELISTOR Tablets FDA-Approved for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

Short Interest Increases 10% For PGNX

Short Interest Increases 10% For PGNX

The most recent short interest data has been released for the 08/15/2016 settlement date, which shows a 930,934 share increase in total short interest for Progenics Pharmaceuticals, Inc. , to 10,136,448, an increase of 10.11% since 07/29/2016.

4 Biotech Stock Charts You Must See

4 Biotech Stock Charts You Must See

Biotech stocks dominate our list of top charts today. Here are four to watch.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Progenics Receives $50 Million Milestone Payment Following FDA Approval Of RELISTOR® Tablets For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-cancer Pain

Company Eligible to Receive Up to $200 Million of Sales Milestone Payments and Ongoing Sales Royalties

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Progenics Pharmaceuticals (PGNX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Progenics Pharmaceuticals (PGNX) as a "perilous reversal" (up big yesterday but down big today) candidate

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

Dow Closes at Record High for 7th Straight Session as Microsoft Surges

The Dow Jones Industrial Average clocks its seventh straight record closing Wednesday amid better-than-expected earnings from Microsoft, the best performing stock in the blue-chip index.

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

These 3 Stocks Are Rising on Big Volume -- Is It Time to Buy?

Here's a look at how to trade some of the most active stocks on the market right now.

S&P 500, Dow on Track to Break Records as Microsoft Surges

S&P 500, Dow on Track to Break Records as Microsoft Surges

Stocks are at record intraday highs by mid-afternoon Wednesday as crude oil trades above $45 and positive quarterly results for Microsoft spread earnings season cheer.

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Midday Report: Valeant Jumps on FDA Approval; Dow at Records

Stocks moved higher, boosted by a series of earnings reports from the likes of Microsoft, Morgan Stanley and United Continental.